KALV - KalVista reaches five-month high as rival tumbles on hereditary angioedema

• The shares of KalVista Pharmaceuticals, Inc. ( NASDAQ: KALV ) reached the highest level since March on Monday after Pharvaris N.V. ( PHVS ), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121.
• An oral bradykinin B2-receptor antagonist, PHA121, is undergoing U.S. clinical studies in HAE under two Investigational New Drug ( IND ) applications for the rare inherited blood disorder.
• KalVista ( KALV ) is also advancing KVD900, its oral therapy for HAE, in a global late-stage trial with data expected in H2 2023.
• Even if PHVS resolves its clinical hold on its HAE candidate, the event will continue to be an overhang to a certain extent and “position KALV well if clinical data next year play out as we hope,” Stifel analyst Paul Matteis, who has a Buy rating and $32, on KALV wrote.
• Read: In April, Japanese pharma giant Takeda ( TAK ), a market leader in HAE, launched its Takhzyro injection for the condition in the U.S.

For further details see: